*A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, SCORE risk (ESC), GFR calculation, ECG and TTE. Measurements of global longitudinal strain and 3D FeVG (if feasible) are recommended with the same machine.
**Refer to the ESC or ACC/AHA risk categories (previous CV diseases + risk factors).
****In some studies, ACE inhibitors might reduce the overall risk of mortality from prostate cancer.
*****In some studies, statins might lower circulating testosterone levels.
Adapted from Bhatha et al, Circulation. 2016;133:537-541